-

Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.

The webcast of the fireside chat will be available on the “Media” section of the Company’s website at www.verastem.com under “Events & Presentations”.

About Verastem Oncology

Verastem Oncology (Nasdaq:VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Contacts

Investors:
Ajay Munshi
VP, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Media:
Lisa Buffington
VP, Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Industry:

Verastem, Inc.

NASDAQ:VSTM
Release Versions
English

Contacts

Investors:
Ajay Munshi
VP, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Media:
Lisa Buffington
VP, Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

More News From Verastem, Inc.

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

BOSTON--(BUSINESS WIRE)--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma...

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--Verastem doses first patient in TARGET-D 201, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated advanced pancreatic cancer...
Back to Newsroom